Our VX-2/Tumor Study is underway and on-track. When the testing is complete data will be presented to the FDA. We contracted Pearl Pathways to be the independent quality control agent as required by the FDA to validate as 'GLP-Like.' We prepared a detailed protocol with key tracking points to ensure compliance with the plan.
News 
Market Data 
Discover 
